nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A Decision Analysis Model Predicts the Optimal Treatment Pathway for Patients with Colorectal Cancer and Resectable Synchronous Liver Metastases
|
Aloia, Thomas A. |
|
2008 |
7 |
3 |
p. 197-201 5 p. |
artikel |
2 |
Adherence to Surveillance Guidelines After Curative Resection for Stage II/III Colorectal Cancer
|
Cheung, Winson Y. |
|
2008 |
7 |
3 |
p. 191-196 6 p. |
artikel |
3 |
Association of K-ras Mutational Status and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Receiving Panitumumab Alone
|
Freeman, Daniel J. |
|
2008 |
7 |
3 |
p. 184-190 7 p. |
artikel |
4 |
Biomarker Validation: In Situ Analysis of Protein Expression Using Semiquantitative Immunohistochemistry-Based Techniques
|
Sullivan, Catherine A.W. |
|
2008 |
7 |
3 |
p. 172-177 6 p. |
artikel |
5 |
Colon Cancer: Update on Adjuvant Therapy
|
Mano, Max S. |
|
2008 |
7 |
3 |
p. 178-183 6 p. |
artikel |
6 |
Highlights from: The 2008 American Society of Clinical Oncology Gastrointestinal Cancers Symposium; Orlando, FL; January 25-27, 2008
|
Grothey, Erin |
|
2008 |
7 |
3 |
p. 165-171 7 p. |
artikel |
7 |
Intussusception in Colorectal Cancer
|
Chand, Manish |
|
2008 |
7 |
3 |
p. 204-205 2 p. |
artikel |
8 |
Is XELOX Equivalent to FOLFOX or Other Continuous-Infusion 5-Fluorouracil Chemotherapy in Metastatic Colorectal Cancer?
|
Douillard, Jean-Yves |
|
2008 |
7 |
3 |
p. 206-211 6 p. |
artikel |
9 |
Molecular Biomarker Development for Anti-EGFR Therapy: Moving Beyond EGFR Expression
|
Chu, Edward |
|
2008 |
7 |
3 |
p. 162- 1 p. |
artikel |
10 |
Selected Clinical Trials in Colorectal Cancer
|
|
|
2008 |
7 |
3 |
p. 212- 1 p. |
artikel |
11 |
Successful Administration of Panitumumab Alone After Severe Infusion Reaction to Cetuximab in a Patient with Metastatic Colorectal Cancer
|
Cartwright, Thomas H. |
|
2008 |
7 |
3 |
p. 202-203 2 p. |
artikel |